Gan & Lee Pharmaceuticals.
603087
주식 순위
#3011
Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused... Gan & Lee Pharmaceuticals is a biopharmaceutical enterprise primarily focused on the discovery, development, manufacturing, and marketing of insulin analogues within the Chinese market. Their diverse product portfolio encompasses injectable therapies such as Basalin (an insulin glargine), Prandilin (an insulin lispro), Prandilin 25 (another insulin lispro variant), Raplin (an insulin aspart), Raplin 30 (an insulin aspart 30 formulation), and Similin 30 (an insulin injection). Beyond diabetes treatments, the company also offers various medical devices. Established in 1998, Gan & Lee Pharmaceuticals maintains its corporate headquarters in Beijing, People's Republic of China. The organization underwent a name change in April 2005, transitioning from its former identity as Beijing Gan & Lee Biotechnology Co., Ltd.
주가
$10.03
시가총액
$5.99B
변동 (1일)
-3.71%
변동 (1년)
2.30%
국가
CN
거래 Gan & Lee Pharmaceuticals. (603087)
카테고리
Healthcare
Gan & Lee Pharmaceuticals. (603087)의 P/S 비율
2026 기준 P/S 비율 TTM: 0
Gan & Lee Pharmaceuticals.의 최신 재무 보고서와 주가에 따르면 현재 P/S 비율(TTM)은 0입니다. 2026년 말 기준 P/S 비율은 0였습니다.
Gan & Lee Pharmaceuticals.의 P/S 비율 기록 (2013 ~ 2026)
매년 말 P/S 비율
| 연도 | P/S 비율 | 변화 |
|---|---|---|
| 2025 | 9.98 | 16.64% |
| 2024 | 8.56 | -25.20% |
| 2023 | 11.44 | 7.09% |
| 2022 | 10.68 | -2.29% |
| 2021 | 10.94 | -50.49% |
| 2020 | 22.08 | 74.82% |
| 2019 | 12.63 | -8.28% |
| 2018 | 13.77 | -0.87% |
| 2017 | 13.89 | -25.30% |
| 2016 | 18.60 | -31.05% |
| 2015 | 26.97 | -23.67% |
| 2014 | 35.34 | -20.02% |
| 2013 | 44.18 | 0.00% |
유사 기업 또는 경쟁사의 P/S 비율
| 회사 | P/S 비율 | P/S 비율 차이 | 국가 |
|---|---|---|---|
| 13.45 | - |
US
|
|
| 2.32 | - |
FR
|
|
| - | - |
JP
|
|
| 2.47 | - |
US
|
|
| - | - |
CH
|
